GSK Arixtra sales in the US only were US$42m for the September quarter and US$111m for the 9mths this year already. The talk was always that Alchemia would get around $38m in sales for the first year @ around 40% market share of GSK sales. By what I am seeing is if we get that 40% of market (average % share generics attract) share we are headed for a lot more than $38m in revenue the first year.
Already we could look at it as US$44m for the 9mths, close to $60m for the full year and that is in $US. Add to that the current rate of exchange another 30% to earnings, though I don't think that the $US will stay that strong for too long. Yes there is a wait for FDA and sales aren't happening until then but we are a heck of a lot closer than most.
Also I can't wait to see how the guys go in New York at the Healthcare Conference, hopefully some insto's take note of the potentials here.
ACL Price at posting:
20.3¢ Sentiment: LT Buy Disclosure: Held
